Inventiva Overhauls Leadership Ahead of Critical MASH Drug Trial Readout
Event summary
- Inventiva appoints three new executives: CFO Axel-Sven Malkomes, CLO Susan Coles, and CPO Pamela Herbster.
- Malkomes previously led finance at CureVac during its BioNTech acquisition.
- Coles returns to Inventiva after prior stints as general counsel and experience at Vivet Therapeutics.
- Herbster joins from Sage Therapeutics, where she managed HR and business operations.
- Phase 3 data readout for lanifibranor in MASH treatment expected Q4 2026.
The big picture
Inventiva's leadership overhaul reflects preparation for a pivotal moment in its history, as the company approaches the Phase 3 readout for its lead asset, lanifibranor. The appointments of executives with deep experience in M&A, regulatory navigation, and commercialization suggest a strategic focus on scaling operations and positioning for potential partnerships or acquisitions. The move comes amid intense competition in the MASH space, where timing and execution will be critical to securing market share.
What we're watching
- Trial Timing
- Whether Inventiva can maintain its Q4 2026 timeline for the NATiV3 Phase 3 data readout, given the complexity of MASH trials.
- Regulatory Pathway
- How the new leadership team will navigate potential regulatory submissions and approvals for lanifibranor.
- Commercial Readiness
- The pace at which Inventiva can build out its commercial infrastructure ahead of potential approval and launch.
Related topics